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Abstract: Therapeutic options for amyotrophic lateral sclerosis (ALS) are still limited. Great hopes,
however, are placed in growth factors that show neuroprotective abilities (e.g., nerve growth
factor (NGF), brain-derived neurotrophic factor (BDNF), and vascular endothelial growth factor
(VEGF)) and in the immune modulating features, in particular, the anti-inflammatory effects.
In our study we aimed to investigate whether a bone marrow-derived lineage-negative (Lin-) cells
population, after autologous application into cerebrospinal fluid (CSF), is able to produce noticeable
concentrations of trophic factors and inflammatory-related proteins and thus influence the clinical
course of ALS. To our knowledge, the evaluation of Lin- cells transplantation for ALS treatment has
not been previously reported. Early hematopoietic Lin- cells were isolated from twelve ALS patients’
bone marrow, and later, the suspension of cells was administered into the subarachnoid space by
lumbar puncture. Concentrations of selected proteins in the CSF and plasma were quantified by
multiplex fluorescent bead-based immunoassays at different timepoints post-transplantation. We also
chose microRNAs (miRNAs) related to muscle biology (miRNA-1, miRNA-133a, and miRNA-206)
and angiogenesis and inflammation (miRNA-155 and miRNA-378) and tested, for the first time,
their expression profiles in the CSF and plasma of ALS patients after Lin- cells transplantation.
The injection of bone marrow cells resulted in decreased concentration of selected inflammatory
proteins (C3) after Lin- cells injection, particularly in patients who had a better clinical outcome.
Moreover, several analyzed miRNAs have changed expression levels in the CSF and plasma of ALS
patients subsequent to Lin- cells administration. Interestingly, the expression of miR-206 increased
in ALS patients, while miR-378 decreased both in the CSF and plasma one month after the cells’
injection. We propose that autologous lineage-negative early hematopoietic cells injected intrathecally
may be a safe and feasible source of material for transplantations to the central nervous system (CNS)
environment aimed at anti-inflammatory support provision for ALS adjuvant treatment strategies.
Further research is needed to evaluate whether the observed effects could significantly influence the
ALS progression.
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1. Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that selectively
affects motor neurons. The typical symptomatic hallmark involves muscle weakness and wasting,
cramps, poor reflexes, twitching, and speech problems. The worldwide incidence is estimated to
be 2–3 per 100,000, and most patients have first symptoms in their sixth and seventh decades [1].
The majority of patients diagnosed with ALS are classified as having sporadic disease, whereas 5–10%
have a positive family history [2]. To date, several genes and loci of major effect have been identified,
and among the known genes, mutations in SOD1 (superoxide dismutase 1) account for 20% of familial
ALS [1].
During the neurodegeneration of ALS, dysfunction occurs at both the motor neuron cell body
and peripheral motor axon. The postulated pathophysiological mechanisms responsible for motor
neurons degeneration involve oxidative stress, excitotoxicity, mitochondrial dysfunction, and protein
aggregates abnormally activating major histocompatibility complex class I [3–5]. Recently, it was
shown that neuroinflammation mediated by glial cells and systemic immune activation may play a
key role in the progression of the disease, through mechanisms that can be either neuroprotective or
neurodetrimental, depending on the type of cells and the motor neuron compartment involved [6].
Several studies have indicated that the immune system is actively involved in the progression of
ALS—CNS, microglia and astrocytes are activated during disease progression, whereas peripheral
T lymphocytes and natural killer cells infiltrate the spinal cord. Previous studies have shown that
many proteins contributing to inflammation and/or the innate immune system may exhibit high levels
in the CSF, plasma, or tissues of ALS patients (e.g., tumor necrosis factor alpha (TNF-α), circulating
chemokines, and cytokines). Among them, toll-like receptors (TLRs) have an important part in
the formation of chronic inflammation in neurodegenerative illnesses such as ALS [7]. It has also
been stated that ALS patients present signs of systemic inflammation, reflected in increased levels of
C-reactive protein (CRP) and complement components, such as C3 and C4 [8,9].
The currently available treatment option for ALS in Poland is riluzole, which prolongs life by
2–3 months with debatable functional improvement [10]. Although the Food and Drug Administration
(FDA) has recently approved the use of edaravone, a free radical scavenger, at this moment, it is not
yet registered in Poland [11]. The broad spectrum of molecular and cellular players in ALS certainly
makes drug development difficult. Recently, increased emphasis has arisen on novel treatment options
for neurodegenerative disorders using stem cell-based therapies, which have been widely investigated
in two major directions: cell replacement and trophic support. The first approach aims at replacing the
degenerated neurons, while the latter claims that stem/progenitor cells (SCs/SPCs, respectively) might
provide a neuroprotective microenvironment for damaged tissue and save the remaining neurons [12].
In recent years, numerous studies have shown that stem cell transplantation elicits neurogenesis and
angiogenesis as stem cells release numerous growth factors, which regulate the growth, differentiation
and migration of neural SPCs [13,14]. It seems that in ALS, in the absence of one specific causative
mechanism identified, the protection of the motoneurons with multipotent growth factors remains
the most rational approach available. So far, the majority of studies and clinical trials in ALS have
been focused on neurotrophic factors, but also other growth factors have been investigated for their
not-so-obvious neurotrophic properties (e.g., vascular endothelial growth factor (VEGF)).
Three distinct families of neurotrophic factors (NTFs) have been characterized in recent years:
classical neurotrophins (e.g., nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF),
neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4)); the glial cell line-derived neurotrophic factor family
of ligands (GDNF), neurturin (NRTN), artemin (ARTN), and persephin (PSPN)); and neuropoietic
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cytokines [15]. Neurotrophins (NTs) possess strong neuroprotective properties and determine
neuronal homeostasis by inducing neural SPCs proliferation, migration, and differentiation via
specific/nonspecific receptor interactions [16]. They are also responsible for the prevention of oxidative
stress and apoptosis inhibition [17]. The accessibility of neurotrophic factors in optimal levels is critical
during development, but they also regulate motor neuron maintenance and survival even long after
neurons have become fully differentiated. NTs might be an interesting treatment tool for various
neurodegenerative disorders; however, their poor pharmacokinetic profiles (primarily their inability to
cross the blood–brain barrier (BBB) and short half-life) make their application in a protein form largely
ineffective [18,19].
Recently, a great therapeutic potential is being attributed to vascular endothelial growth factor
(VEGF), which, on the contrary to NTs, does cross the BBB in sufficient concentrations [20]. Besides
its prominent role in angiogenesis, VEGF also exerts important protective effects on neurons. VEGF
promotes the survival of cells overexpressing a mutated SOD1 G93A protein [21,22] and ameliorates
the effects of glutamate excitotoxicity [23]. In rodents, VEGF treatment leads to a delay of ALS onset,
an improvement of motor functions, the protection of motoneurons and neuromuscular junctions,
and increase in survival [24,25]. Overall, pre-clinical data on the VEGF role in ALS treatment
is promising.
Multiple mechanisms regulate proper levels of protein expression; among these, microRNAs
(miRNAs, miRs) are commonly seen as ‘master regulators’ [26]. MiRNAs are small, non-coding
molecules, which regulate gene expression at the post-transcriptional level, usually binding the
3′-untranslated region of mRNA sequence [27]. Apart from their recognized role in cellular
specification and pathophysiological mechanisms, the recent discovery of circulating miRNAs
also suggests that they provide novel means for paracrine and systemic communication [28].
In regards to ALS, recent studies have shown a correlation between miRNAs expression and
microglia activation [29]. A group of muscle-specific miRNAs (“myo-miRs”) including miRNA-1,
miRNA-206, and miRNA-133a/b, which are involved in the process of proliferation, plasticity,
regeneration, and repair of muscle [30], might play a role in modulating the disease course in
ALS, where degeneration of both upper and lower motoneurons leads to muscle atrophy. Recent
findings also demonstrate a presumable role of other groups of miRNAs, including immune
system-related miRNAs (“immuno-miRs”), such as miRNA-155 [31,32], and angiogenic-related
miRNAs (“angio-miRs”), such as miRNA-378 [33], in ALS pathology. In this study, we chose
to investigate the expression levels of miR-1, -133a, -155, -206, and -378 for their role in the
pathophysiological processes in ALS. To our knowledge, miRNA expression in the physiological
fluids of ALS patients during the course of experimental lineage-negative (Lin-) cell therapy has not
been studied so far.
We have previously shown that umbilical cord blood (UCB)-derived SPCs, especially Lin- cells,
strongly and specifically express classical NTs and the novel neurotrophic cytokines: cerebral dopamine
neurotrophic factor (CDNF), mesencephalic astrocyte-derived neurotrophic factor (MANF), pigment
epithelium-derived factor (PEDF), and the aforementioned VEGF. We have also shown that these
secreted factors support neuronal proliferation and in vitro survival in a conditioned medium from
Lin-SPCs [14]. In this study, we aimed to investigate whether bone marrow-derived Lin- cells
administration is safe and feasible in ALS patients. Because miRNAs and growth factors have a
strong role in ALS pathology, we hypothesized that this adjuvant cell therapy could also bring specific
changes in the expression profiles in both the CSF and blood plasma of ALS patients.
2. Results
2.1. Analysis of Included Individuals
Four females and eight males suffering from ALS were enrolled in the study. The demographic
and neurological characteristics of the ALS patients are shown in Table 1. There were no abnormalities
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on the laboratory tests at the inclusion to the study. Clinical analysis was performed in 12 patients as
described in Section 4. All ALS patients enrolled in this trial were treated once with autologous bone
marrow-derived lineage-negative early hematopoietic cell transplantation given intrathecally to the
spinal canal and were assessed for therapy safety and for analysis of selected growth factors, cytokines,
and miRNA profiles expressed in the blood plasma and cerebral spinal fluid. In our previous studies,
we have thoroughly characterized Lin- cells as a heterogeneous population, which consists of precursor,
progenitor, and stem cells and lacks mature morphotic blood elements [15]. Of note, inter-individual
variability related to the number of Lin- cells isolated from the bone marrow from each ALS patient
and subsequently transplanted intrathecally underlines the heterogeneity of the study patients’ groups
(Table 1). In three months post-transplantation, 12 patients were retrospectively analyzed in detail as
described in Section 4. As a result of such investigation, the whole patient population was divided into
two different groups based on the disease course post-transplantation. Group I included six patients
who did not decline neurologically after Lin- cells transplantation. In contrast, group II consisted
of six patients, who presented deterioration of neurological status despite cellular adjuvant therapy.
Then, in the context of the ALS course, further analysis of molecular data was performed separately
for both groups and compared together. Initial comparison of the anthropometric parameters between
both groups of treated individuals revealed no statistically significant differences (Table 1). In our
study, patients from group II appeared to obtain lower number of Lin- cells per transplantation than
individuals from group I.
Table 1. Characteristics of both groups together with the amyotrophic lateral sclerosis functional rating
scale (ALSFRS) and Norris scale results. Tx: transplantation.
Characteristic Group I (n = 6) Group II (n = 6) p-Value
Age (mean ± SD, years) 48.7 ± 15.5 50.7 ± 10 p = 0.8133
Age at disease onset (mean ± SD, years) 45.5 ± 17 47.3 ± 10.4 p = 0.8141
Sex (male/female) 4/2 4/2 p = 1
Symptom duration (mean ± SD, months) 39.3 ± 27.39 37.3 ± 32.14 p = 0.9178
Number of Lin- cells administered (mean ± SD) 11.95 ± 5.76 × 106 4.53 ± 3.19 × 106 p = 0.0365
ALSFRS score (mean ± SD)
Before Lin- Tx 26.3 ± 2.8 15.5 ± 3.15 p = 0.0002
3 months after Lin- Tx 25.5 ± 3.6 12.6 ± 1.7 p = 0.0002
6 months after Lin- Tx 23 ± 6.4 10.5 ± 1.5 p = 0.0491
Norris scale score (mean ± SD)
Before Lin− Tx 84.3 ± 4.4 58 ± 6.4 p < 0.0001
3 months after Lin- Tx 86 ± 5.9 50.3 ± 3.7 p < 0.0001
6 months after Lin- Tx 81.6 ± 12.2 38 ± 6.6 p = 0.0007
We have not observed any adverse effects of autologous bone marrow-derived Lin- cells injected
intrathecally, which makes them a safe and feasible source of material for transplantations to the CNS
environment aimed at trophic support provision. The characteristics of both groups are shown in
Table 1. Laboratory tests were performed on the obtained peripheral blood samples, and the results
are presented in the Supplementary Materials.
2.2. Growth Factor Levels in CSF
The concentrations of inflammatory proteins (C3, C4, and CRP), neurotrophic factors (NGF and
BDNF), and growth factors involved in angiogenesis (ANGP2 and VEGF) were assessed (Figure 1).
We found that levels of C3 were significantly lower (up to two times) after Lin- cells transplantation
in ALS patients from group I than before transplantation (Tx). In contrast, C3 concentration after
Lin- cells transplantation in ALS patients from group II was significantly higher than before cell
administration (Figure 1). Interestingly, when we compared the levels of C3 before cell therapy in
patients diagnosed with ALS from both groups included in the study, we observed significantly higher
(up to two times) C3 concentration in patients from group I. In addition, the analysis of the initial
concentration of C4 before Lin- cells transplantation revealed a 50% increase in the individuals from
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group II. We observed no significant differences in the levels of neurotrophic (NGF and BDNF) and
angiopoietic (ANGP2 and VEGF) growth factors between the individuals from both groups of patients
diagnosed with ALS neither before nor after Lin- cells transplantation (Figure 1). However, we cannot
compare the obtained data with the control group values due to the lack of a control group for the
procedure in this preliminary study, which is explained in Section 3.Int. J. Mol. Sci. 201, 1, x  5 of 19 
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4. * p < 0.05,  ** p < 0.01—level of significance. CRP: C‐reactive protein; NGF: nerve growth  factor; 
BDNF:  brain‐derived  neurotrophic  factor;  ANGP2:  angiopoietin  2;  VEGF:  vascular  endothelial 
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2.3. Comparison of Systemic Levels of Neurotrophic Growth Factors in Blood Plasma from ALS Patients 
Using multiplex immunoassay, we have also assessed the levels of NGF and BDNF in plasma 
samples (Figure 2). We have observed that in group I, NGF levels considerably increased in the first 
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the  lowest  concentration  in  six  months  post‐transplantation  at  the  end  of  the  investigation. 
Figure 1. Levels of selected growth factors and cytokines in ALS patients’ CSF at different timepoints
(0 months: before Lin- cells transplantation, 1 month: 1 month after Lin- cells transplantation) and
their statistical comparison. A description of the difference between group I and II is given in Section 4.
* p < 0.05, ** p < 0.01—level of significance. CRP: C-reactive protein; NGF: nerve growth factor;
BDNF: brain-derived neurotrophic factor; ANGP2: angiopoietin 2; VEGF: vascular endothelial growth
factor. Symbols (solid circle, triangle, square) are used to distinguish groups, each symbol represents
one patient.
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2.3. Comparison of Systemic Levels of Neurotrophic Growth Factors in Blood Plasma from ALS Patients
Using multiplex immunoassay, we have also assessed the levels of NGF and BDNF in plasma
samples (Figure 2). We have observed that in group I, NGF levels considerably increased in the first
days after cells injection; however, they began to gradually decrease after a week, presenting with the
lowest concentration in six months post-transplantation at the end of the investigation. Interestingly,
in group II of ALS patients, the levels of NGF were considerably decreased in all study time-points
compared with the corresponding time-points in group I before and after cell therapy. General tendency
in the changes of concentration of BDNF in plasma were similar in both groups; although, in group I,
we have noted an increase in BDNF level in the third day post-transplantation (from 1382.6 pg/mL to
2588.4 pg/mL). In group II, the upswing was much lower indeed (from 915.6 pg/mL to 1172.0 pg/mL).
However, the only statistically significant difference was observed for NGF in group I (three days vs.
six months), but the interpretation must be cautious due to the large variation in the levels of NGF,
the small number of patients investigated, and the lack of a control group.
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Figure 2. Levels of selected neurotrophic growth factors in ALS patients’ blood plasma at different
timepoints (0, 3, and 7 days and 3 and 6 months after the experiment onset) and their statistical
comparison. Description of the difference between group I and II is given in Section 4. * p < 0.05—level
of significance. Symbols (solid circle, triangle, square) are used to distinguish groups, each symbol
represents one patient.
2.4. miRNA Expression
Our results of miRNA expression analysis in the CSF and plasma are depicted in Figures 3 and 4
respectively. We found that in the CSF, the expression levels of miRNA-206 were significantly higher
(up to two times) in ALS patients from both groups after cell transplantation compared to the initial
timepoint before Lin- cells administration. Interestingly, relatively similar significant results were
observed in case of miRNA-133a in both groups of ALS patients before and after cell Tx. In contrast,
we found that levels of miRNA-378 were significantly lower one month after Lin- cells therapy in
both groups of ALS patients. We did not detect any difference between experimental timepoints when
analyzing the expression pattern of miRNA-1 and miRNA-155 in the CSF.
Next, we became interested in systemic levels of selected miRNAs in the peripheral blood plasma.
We found that in plasma, the expression levels of miRNA-155 were significantly higher (up to two times)
in ALS patients from both groups after cell transplantation compared with the initial timepoint before
Tx of Lin- cells. Furthermore, in group II of ALS patients, we detected a similar expression pattern in
case of miRNA-206 before and after cell administration. In group I of ALS patients, miRNA-206 was
also increased nearly 100% after Lin- cells Tx compared with the initial timepoint; however, in this case,
the difference did not reach statistical significance. In contrast, we found that levels of miRNA-378
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were significantly lower (maximally up to three times) one month after Lin- cells therapy in both
groups of ALS patients. Likewise, Lin- cells administration induced a significant decrease of miRNA-1
expression in group II of ALS patients one month post-injection. We did not detect any difference
between experimental timepoints when analyzing the expression pattern of miRNA-133a in plasma.
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Figure 4. Mean relative values of miRNA expression in ALS patients’ blood plasma (0 months: before
Lin- cells transplantation, 1 month: 1 month after Lin- cells transplantation); * p < 0.05, ** p < 0.01,
*** p < 0.001. Symbols (solid circle, triangle, square) are used to distinguish groups, each symbol
represents one patient.
3. Discussion
ALS is an incurable neurodegenerative disease, and despite the substantial number of approaches
that have been tested clinically, therapeutic options are still limited. Many hopes for the cure for
ALS are placed in growth factors that show neuroprotective abilities and are known to promote the
survival of neurons (e.g., NGF, BDNF, and others). However, their plasma delivery in pure protein
form is rather ineffective, often due to their poor pharmacokinetic profiles and inability to cross the
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blood–brain barrier in substantial amounts [34]. Therefore, in ALS, different stem and progenitor cell
therapy approaches step forward, as stem cells are avid growth factors ‘producers’. Human intrathecal
transplantation of different stem cell populations, including bone marrow (BM)-derived hematopoietic
stem and progenitor cells, have been previously attempted in patients with ALS, as well as in other
neurological disorders, such as stroke, cerebral palsy, or injury of the spinal cord, with promising
results and no relevant complications [35,36]. Importantly, in the experimental studies with stem
cell therapies performed in ALS patients, different quantities of cells were transplanted, even in the
same cohorts of subjects, due to the limited number of isolated cells available for a given patient,
however, with good study outcomes [37]. In this study, we investigated the safety and feasibility of
the administration of, previously described by our team [15], lineage-negative early hematopoietic
progenitor cells derived from each patient’s own bone marrow and their influence on the clinical
course of ALS through the first, to our knowledge, intrathecal transplantation of Lin- cells at different
doses to ALS patients. This selectively isolated cell population shows long-term self-renewal and
paracrine secretion of various angiopoietic and neurotrophic factors [14,38,39] on much higher levels
than do other nucleated cells [15]. Therefore, we have focused on potential/suggested trophic activity
exerted by transplanted Lin- cells in a neural environment rather than on their direct engraftment and
replacement of degenerating neurons in the nervous system affected by ALS. We have also tested for
the first time whether Lin- cells transplantation might influence specific miRNA expression patterns
observed in the CSF and in the peripheral blood plasma of ALS patients.
The important role of neuroinflammation mediated by glial and immune cells that are
active players in the pathogenesis of ALS is emerging [17]. Therefore, we have focused first on
neuroinflammation in our ALS patient population, as numerous inflammatory proteins have been
previously shown to be altered by this disease [40,41]. In our study, there were significant differences
in C3 and C4 concentration between study groups. Importantly, before cell transplantation, group
I presented higher C3 and lower C4 levels than group II. After Lin- cells transplantation, C3 levels
decreased in group I, but increased in patients from group II, whose neurological condition deteriorated
in course of ALS.
It was reported from the analysis of postmortem ALS spinal cord tissue that a robust complement
activation has been detected at RNA and protein levels in ALS patients, leading to increased amounts
of different activated complement components in the CSF and plasma, as well as directly in the spinal
cord [42,43]. Sta et al., have recently suggested that there is disruption of the balance of clearance
and repair in the CNS of ALS patients, which involves the complement system [44]. In a model of
immune activation in ALS proposed by this group, the stressed neurons and the surrounding glial
cells produced complement C1q and C4. C4 has been also shown to play a role in the attraction and
activation of macrophages in SOD1 mutant mice [45]. C1q represents the initiating component of the
classic complement pathway (C1→C4/C2/C3→C5) [46], whereas C3 is central to the classic and the
alternative complement pathway (C3→C3/B→C5) [47]. Although most complement components
are produced by the liver, many different cell types, including CNS microglia, specific neuronal
populations, and astrocytes, can produce C3 and C4 [48]. Activation of the complement system and
pro-inflammatory microglia may result in the impairment of the BBB; therefore, the increased levels of
C3 and C4 in the CSF in ALS might result from both the increased intrathecal synthesis and the influx
from the systemic circulation.
Several studies in ALS mice models have correlated the increase in complement components with
the disease progression, which might in part also explain our findings. In a recent study, deletion of the
gene encoding C4 did not affect the disease course in high-expressing mutant SOD1G93A mice [45];
however, the C3-dependent alternative complement pathway activation would still be possible.
Local activation and increased expression of complement components signaling can contribute also
to the recruitment of different mononuclear cells, including macrophages, that might accelerate
the neuronal death, as observed in SOD1G93A mice [49]. In this notion, previously described
selective inhibition of C5a–C5aR1 signaling ameliorated ALS pathology, reduced motor symptoms,
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and extended the survival of SOD1G93A mice [50]. Likewise, in our recent study on the constitutive
C3-deficiency in the neural retina, it was found that the lack of activated C3 resulted in lower expression
of the cellular oxidative stress components and higher anti-apoptotic activity together with significantly
increased expression of several gene sets associated with the maintenance of the physiological functions
of the nervous system [51]. Our actual observation of the significantly decreased C3 levels in the CSF
in group I after Lin- cells administration may suggest temporary inhibition or at least a slowdown
of neuroinflammatory processes, perhaps at least partially induced by Lin- cells transplantation.
In contrast, the increase of C3 expression in group II of ALS patients might be a reflection of continuous
local complement activation, which was not blocked sufficiently by the Lin- cells therapy approach.
It should be stressed here that group II of ALS patients obtained a lower number of Lin- cells during
transplantation in general compared to the ALS individuals representing group I in our study.
Neurotrophic factors have been at the center of interest in ALS research for years. Neurotrophins
are proposed as potential drugs and have been used in multiple approaches to decrease the disease
progression in human, as well as in animal models [52–56]. In our study, we have observed that a single
injection of Lin- cells does not result in a prolonged change of BDNF and NGF levels in the CSF. In fact,
due to the short half-life of both molecules, it might be the case that their concentrations in the CSF have
changed shortly after cell injection, but in this study we examined the CSF collected before the Lin- cells
transplantation and after one month, which could have been too distant a timepoint to observe actual
changes in these proteins’ concentrations. We can expect that the potential beneficial effects of elevated
neurotrophins concentrations in the CSF of ALS patients may possibly be prolonged with repeated cell
injections, but this approach would require additional cell isolations and further monitoring timepoints.
Nevertheless, a portion of NTs released by the administered Lin- cells might as well infiltrate from the
CSF through the BBB and thus temporarily influence the local NTs synthesis within other cells, mostly
in patients from group I, who received a greater number of Lin- cells. Interestingly, we previously
observed that the exposure of Lin- cells to NTs, could increase the local expression of other NTs, such
as NT-3 expression following BDNF exposure [57]. Therefore, the detected plasma concentration of
BDNF and NGF might be a reflection of a systemic response after Lin- cells transplantation but could
also arise from increased expression of NGF in skeletal muscle [58] or altered astrocyte–motoneuron
cross-talk [59]. The observed results might also be due to generally low, often undetectable, levels
of these proteins in the blood plasma [60], which make NTs concentration assessment challenging.
This hypothesis is supported by the fact that transcripts for BDNF are strongly downregulated in
muscle biopsies from ALS patients [61]; thus, the NTs released from Lin- cells may just cover the
basic demands for these regulatory proteins in the nervous system and other tissues of ALS-affected
human organisms.
MiRNAs operating as fine tuners of post-transcriptional events mediate neuronal gene expression,
and their dysregulation becomes instrumental for understanding many diseases [62,63], including
ALS. ALS is a motor neuron disorder, and it has been proven in various reports that ALS can be caused
due to dysregulation of miRNAs and thus misexpression of proteins in cells. Recently, it has been
postulated that disrupted signaling at the neuromuscular junction, caused by cytotoxicity associated
with abnormal glutamate clearance and an overactive inflammatory response, results in neuromuscular
degeneration. Dysregulation of key miRNAs triggers the alterations in motor neuron physiology,
resulting in ALS pathology. Therefore, in the present study, we tested the expression profiles of
five chosen miRNAs (myo-miRs, angio-miRs, and immuno-miRs) in the plasma and CSF of patients
at two timepoints: before Lin- cells transplantation and a month after. Previous studies have also
stressed that microRNA profiling in ALS patients is largely dependent on the disease duration and the
patient’s sex and age at onset [64], and all these factors might have influenced our results. Overall,
we have observed similarities in miRNA profiles between groups I and II. Because the number of
Lin- cells transplanted varied between the groups, our miRNA results may suggest that the number of
transplanted cells is not a main factor influencing miRNA profiles. However, the significant changes
of several miRNA expression levels after Lin- cells administration may represent subtle neurological
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mechanisms modifications induced by the presence of biologically active Lin- cells in the area of
the central nervous system after their intrathecal transplantation. Nevertheless, several miRNAs
investigated in this study could potentially serve as biomarkers of disease activity and confirm
previous observations in this field of molecular neurology.
In the group of myo-miRs, the key regulator of the signaling between the motor neurons and
skeletal muscle fibers at the neuromuscular synapses is miR-206—a skeletal muscle-specific microRNA
affected in course of ALS. It has been found that deficiency of miR-206 in the ALS mouse model
(SOD1G93A mice) accelerates disease progression, as miR-206 is required for efficient regeneration of
neuromuscular synapses after nerve injury, which process probably accounts for the salutary effects
in ALS. Of note, miR-206 mediates these effects through histone deacetylase 4 and fibroblast growth
factor signaling pathways in ALS-affected muscle cells [65]. In our study, the expression levels of
this molecule were altered in all ALS patients recruited to this study, and we observed a significant
increase in miR-206 levels one month after Lin- cells transplantation among both groups of ALS
patients (groups I and II). Importantly, a similar pattern of expression changes in both study groups
was observed after Lin- cells transplantation and also in case of another myo-miR—miR133a. Increased
expression levels of both analyzed myo-miRs post-transplantation could have positive regulatory
effects by promoting the formation of new synapses that may delay the progression of ALS in our
patient cohort after Lin- cells transplantation. This observation is in concordance with the findings of
previous studies that muscles upregulate these miRs in a futile attempt to promote reinnervation after
their damage and thus resist disease progression [65].
Neuroinflammation and glial cell activation have been shown to contribute to motor neuron
degeneration in ALS. The upregulation of “inflamma-miRNAs”, also known as “immune-miRs”,
including miR-155, was shown to contribute to microglia-mediated immune response and
neuroinflammation [66]. Thus, after Lin- cells administration we defined alterations of miR-155
expression, noticeably important for neuroinflammation-associated signaling pathways in ALS.
Interestingly, we found that the significant increase of miR-155 expression levels was a sustained
feature only in the blood plasma collected from all ALS patients after Lin- cells transplantation but not
in their CSF samples. The constant expression profile of miR-155 in the CSF after cell transplantation
might vaguely suggest that the inflammation is not progressing [67] after cell transplantation. On the
other hand, there is recent evidence demonstrating that upregulation of miR-155 benefits in preventing
the elevation of other pro-inflammatory cytokines. The miR-155 upregulation could be due to the
lack of CX3CL1 inhibitory input from neurons, essential for the microglia surveilling phenotype [68].
In addition, the protective and anti-inflammatory role of miR-155 was recently suggested in the model
of atherosclerosis-associated chronic inflammation [69]. Therefore, the results of miR-155 expression in
our study may provide a potential explanation for the observed significantly lower concentration of
pro-inflammatory C3 molecule in the CSF from ALS patients after Lin- cells transplantation.
MiR-378 is strongly implied in adipocyte gene expression and lipogenesis [70]. Taken above,
miR-378 might regulate adiponectin expression through a C/EBP binding site of the adiponectin
promoter [70]. MiR-378 is significantly upregulated in muscle cachexia, which can gradually develop
in patients affected by ALS. The expression of miR-378 associates strongly and positively with
catecholamine-stimulated lipolysis in adipocytes. This correlation is probably causal, because
overexpression of miR-378 in human adipocytes increases catecholamine-stimulated lipolysis.
Taken together, increased miR-378 expression in ALS patients could play an etiological role in
degenerative cachexia-associated adipose tissue loss via effects on adipocyte lipolysis. In contrast,
inhibition of miR-378 expression could attenuate stimulated lipolysis and reduce the expression of
a set of genes (LIPE, PLIN1, and PNPLA2) encoding key lipolytic regulators [71]. In our study,
we observed the significant decrease of miR-378 expression in all ALS patients following Lin- cells
transplantation, which might have an effect on the clinical outcomes in this patient cohort. Finally, some
studies have also linked the aforementioned miR-378 with inflammation processes [72,73], as generally
both lymphoid- and myeloid-related cells affect inflammation in a stimulating or inhibitory manner.
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In this notion, it is interesting whether the results of the miR-378 expression obtained in our study
after cell transplantation may provide another potential explanation for the observed significantly
lower concentration of pro-inflammatory C3 molecules in the CSF of ALS patients from group I,
which obtained a greater quantity of Lin- cells during the Tx procedure.
Although our study groups were too small to validate the specificity and sensitivity of the selected
miRNAs as biomarkers, on the basis of our results one can conclude that one of the miRNA profiling
assets in ALS is consistency of expression tendencies in the CSF and plasma. However, we cannot
compare the obtained data with control group values due to the lack of a control group for the
procedure in this preliminary study, which is explained below. We propose, that miRNA-155, -206,
and -378 could serve as useful biomarkers of ALS response to bone marrow-derived cell therapeutic
administration, but this needs further elucidation. However, for each of the analyzed miRNAs,
whether the change contributes directly to disease progression or represents a compensatory/beneficial
response to cell therapy remains unclear. In particular, this is a first study of miR-378 in ALS, and a
vast spectrum of miR-378 targets could provide a link between various processes underlying ALS
pathophysiology. In our future studies, we will aim to further investigate the emerging role of miR-378
in ALS and its potential in diagnosis, treatment, and prognosis.
Potential Study Limitations
Overall, our study gave some interesting results, but it did not lack some drawbacks. The first is
the diversity of the investigated group—patients enrolled in the study differed considerably in terms
of the disease onset (17–62 years), ALS disease duration (8–108 months), and the number of available
Lin- cells transplanted into each particular patient. Also, due to the characteristics of our study based
on Lin- cells injection, the experiment was conducted only in ALS patients, lacking a control group.
Overall, this study was not designed, nor was large enough, to determine the efficacy of slowing or
stopping the progression of ALS. In addition, the clinical progression in ALS is highly variable, and the
biological factors accounting for this variability are still unknown. Therefore, for proper reasoning,
we divided the study cohort arbitrary into two separated groups, which included only six participants,
related to their clinical outcomes, further limiting our ability to make any conclusive statements
about the therapeutic efficacy of the Lin- cells transplantation. We could only observe in these small
groups the changes in molecular expression of selected proteins and miRNAs. Nevertheless, we must
be cautious about ascribing the cause and effect of the performed intervention to the ALS patients
recruited to the study. In the absence of a control group, it remains unclear whether changes in these
parameters were due to the injected cells themselves or a response of the host tissue. Additional
studies are warranted to address this study limitation.
4. Materials and Methods
4.1. Patients
The study was designed as a prospective, open-label, nonrandomized clinical trial in a single
center for subjects with ALS. The trial (international number: NCT02193893) was approved (approval
code: KB-0012/06/10; 25 January 2010) by the Ethics Committee of the Pomeranian Medical University
in Szczecin (Poland) and performed in accordance with the Declaration of Helsinki; all patients
provided written informed consent. A total of 12 patients, four females and eight males, between 21
and 65 years old (49.7 ± 13.08), with sporadic ALS according to the El Escorial Revised Criteria [74]
and with a survival prognosis of over 12 months on the basis of general and neurological condition
were enrolled in the study. A three-month period after the enrollment was dedicated to natural history
observation, during which controlled administration of riluzole (the only ALS treatment registered
in Poland) was continued. Patients over 65 were excluded from the study, as it has been previously
demonstrated that cell growth of expanded in vitro stem cells is strictly related to the donor’s age [75].
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Patients with familial ALS, with evidence of any concurrent illness, or receiving any medications that
might affect bone marrow were excluded.
4.2. Assessment
The clinical progression of the disease using the Norris scale was assessed at baseline, after 1, 2,
3, 5, 7, and 12 days (during hospitalization), 18 and 28 days after injection, and three and six months
after injection. This scale is a rating scale for ALS and consists of two parts, the limb Norris scale
(21 items to evaluate extremity function) and the Norris bulbar scale (13 items to evaluate bulbar
function). Each item is rated in four ordinal categories. In addition, activities of daily living using the
amyotrophic lateral sclerosis functional rating scale (ALSFRS) were assessed prior to the cell therapy,
at discharge from the clinic (day 12), and during subsequent visits. The ALSFRS scale measures a
patient’s level of self-sufficiency in four domains with three items in each (rated 4–0 with a maximum
score = 48): bulbar function, fine motor tasks, gross motor tasks, and respiratory insufficiency. Based
on the functional condition of patients three months after cell injection (assessed using the ALSFRS and
Norris scale), we divided them into two groups: I—patients whose condition did not decrease based
on results from at least one scale assessment (n = 6); and II—patients whose condition deteriorated
based on results from both neurological tests (n = 6).
4.3. Cells
BM from the patients was obtained after informed consent was given. BM samples (40–50 mL)
were aspirated in local anesthesia, from the posterior iliac crest of recruited patients and subsequently
resuspended in a collecting medium (phosphate-buffered saline (PBS), pH 7.2) and heparin (20 U/mL;
Gibco, Waltham, MA, USA). BM samples were lysed in BD PharmLyse Lysing Solution (BD Biosciences,
San Jose, CA, USA) for 15 min at room temperature in the dark and washed twice in phosphate-buffered
saline. The obtained suspension of BM nucleated cells (NCs) was subjected to immunomagnetic
separation procedures (MiniMACS, Miltenyi Biotec, Auburn, AL, USA). Lineage-negative SPCs
(7.89 ± 5.77 × 106) were isolated from non-separated NCs using immunomagnetic isolation and
a lineage cell depletion kit (Miltenyi Biotec, Auburn, AL, USA), as described [15], according to the
GMP conditions. Before implantation, the cells were maintained in 2 mL of sterile PBS.
4.4. Administration Procedure
The suspension of Lin- SPCs in PBS (2 mL) was administered into the subarachnoid space
by lumbar puncture between the lumbar vertebrae L3/L4 or L4/L5. The number of Lin- SPCs
administered differed between the groups: group I received 11.95 ± 5.76 × 106 cells, while group II
received 4.53 ± 3.19 × 106 cells. The cell suspension was slowly injected into the subarachnoid space
for 2–3 min. Then, patients were maintained in a supine position for 24–48 h.
4.5. Safety Endpoints
We assessed the safety of Lin- SPCs transplantation by the development of immediate or delayed
adverse events. Immediate reactions included respiratory failure, allergic reactions, local complications,
systemic complications, paralysis, or sensory loss below the level of the injection site. Delayed reactions
included intraspinal tumor formation or syringomyelia, persistent sensory loss, or paralysis not due to
the progression of the disease.
4.6. Molecular Analysis
For the molecular assays, we collected peripheral blood and cerebrospinal fluid samples at
different timepoints: peripheral blood was collected on the day of cell transplantation (day 0), three
days, seven days, one month, three months, and six months after transplantation, while CSF was
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collected on day 0 and one month after the procedure. The peripheral venous blood (ca. 10 mL) was
collected into tubes containing EDTA as an anticoagulant.
4.6.1. Multiplex Assay
Concentrations of various factors (BDNF, NGF, CRP, C3, C4, ANGP2, and VEGF) in the CSF were
quantified by multiplex fluorescent bead-based immunoassays (Luminex Corporation, Austin, TX,
USA) in samples collected on the day of the cell injection and one month later. Additionally, we also
assessed levels of BDNF and NGF in patients’ plasma on the day of injection, three and seven days
after treatment, and three and six months after treatment. The procedure was performed according to
the manufacturer’s protocol, as previously described [76].
4.6.2. qRT-PCR
miRNA isolation and expression analysis was performed in the cerebrospinal fluid, and blood
plasma was collected before cell administration and one month after cell transplantation. miRNA
was isolated from the plasma (200 µL) and cerebrospinal fluid (200 µL) with the NucleoSpin®
miRNA Plasma Kit (Macherey Nagel, Düren, Germany), following the manufacturer’s protocol.
Total miRNA was eluted in 30 µL nuclease-free water. Next, 25 fmol of miR-39 from C.elegans
(sequence: 5′-TCACCGGGTGTAAATCAGCTTG-3′, synthetized by the Institute of Biochemistry
and Biophysics, Polish Academy of Sciences) was added to each sample as a spike-in control.
Next, reverse transcription was performed with 7 µL of samples using NCode miRNA First-Strand
cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer’s
protocol. Subsequently, preamplification was performed as described in Jazwa et al. [77]. Quantitative
assessment of the expression of the selected miRNAs (miRNA-1, miRNA-133a, miRNA-155,
miRNA-206, and miRNA-378) was performed by qRT-PCR using 2 µL of 10× diluted samples obtained
after preamplification, SYBR Green PCR Master Mix (SYBR Green qPCR Kit, Sigma-Aldrich, St. Louis,
MO, USA), a universal reverse primer for miRNAs qPCR supplied with NCode miRNA First-Strand
cDNA Synthesis Kit, and miRNA specific primers. Relative quantification of expression of selected
target miRNAs was performed with the comparative Ct (cycle threshold) method. The relative
quantization value of the target, normalized to spike-in control, was expressed as 2−∆Ct.
4.7. Statistical Analysis
GraphPad Prism software (v.6.1) was applied for all mathematical calculations, including
mean and standard deviation. ANOVA with post-hoc Tukey’s test was used to calculate statistical
significance; a p-value < 0.05 was considered significant.
5. Conclusions
We have shown that autologous bone marrow-derived lineage-negative early hematopoietic
cells injected intrathecally are a safe and feasible source of material for transplantations to the
CNS environment aimed at trophic support provision. Lin- cells intrathecal injection appeared
to be a safe and well-tolerated procedure without transient or chronic adverse events. Therefore,
with proper enrollment criteria and repeated cell applications, it may be possible to sustain their
potentially beneficial effects, thus causing a gradual decrease or stop in ALS progression. Despite
the variation in individual response arising, inter alia, due to different stages of the disease during
enrollment, our preliminary results suggest that single intrathecal injection of bone marrow-derived
early hematopoietic cells may cause some positive changes in various cytokines concentrations.
Furthermore, our findings showed consistent miRNA expression profiles in the CSF and blood plasma,
providing some presumable links between miRNA expression and the effects on the disease pathology;
however, this needs further clarification. These data suggest that miR-206 or miR-133a in the CSF may
also have a specific protective function at the synapse in ALS, where denervation occurs following
motor neuron cell death. To our knowledge, this is the first study on miRNA-378 in ALS, which might
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potentially serve as a biomarker of disease progression. In our future studies, we aim to further
investigate the role of miRNA-378 and its targets in the pathophysiology of ALS.
Further clinical and experimental studies need to be conducted in the future to fully define
the exact molecular roles of different miRNA in the pathogenesis of different forms of ALS disease
in humans. The use of miRNAs as disease biomarkers may have strong potential, not only for
early diagnosis, but also for predicting disease severity and evolution and for improving phenotype
classification and group stratification in the planned clinical trials.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/5/
1312/s1.
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ALS amyotrophic lateral sclerosis
ALSFRS the amyotrophic lateral sclerosis functional rating scale
ANGP2 angiopoietin 2
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CNS central nervous system
CRP C-reactive protein
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GDNF glial cell line-derived neurotrophic factor
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